Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib for Advanced Malignant Tumors with CTC Evaluation
ChiCTR-OPC-17011248Phase 4Recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- May 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in cancer, sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Circulating tumor cells. Started May 2017; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
cancer
Beyond the preview
Go deeper on ChiCTR-OPC-17011248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17011248.